Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Type One Clear all

Conditions: Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Bone Metabolism
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 70 Years · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 34
States / cities: Greenbrae, California • Los Banos, California • San Diego, California + 31 more

Conditions: Obesity, Type 2 Diabetes
Interventions: Cagrisema, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 99
States / cities: Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glulisine, Insulin Glargine, Premixed Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: VisionQuest Biomedical LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Albuquerque, New Mexico • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app; Device
Lead sponsor: LifeScan; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 14 Years to 40 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Obesity or Overweight
Interventions: AZD6234, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 33
States / cities: Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more

Conditions: Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
Interventions: iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes
Interventions: Tagatose, Sugar Substitute Splenda; Drug
Lead sponsor: Robert Lodder; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 21
States / cities: Hueytown, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 18 more

Conditions: Diabetes Mellitus, Type I
Interventions: Real-time glucose sensor; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 3 Months to 3 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: GSK189075; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more

Conditions: Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy, Neurotoxicity, Post Transplant Diabetes
Interventions: Liver biopsy; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Escondido, California • Lincoln, California • Walnut Creek, California + 19 more

Conditions: Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 77 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 77
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more

Conditions: Diabetes Mellitus
Interventions: Inhaled insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 88
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more

Conditions: Diabetes Mellitus, Type 2
Interventions: ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin, Liraglutide; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Little Rock, Arkansas + 28 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Lispro low mixture; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 13
States / cities: La Jolla, California • Walnut Creek, California • New Britain, Connecticut + 10 more

Search by objective public record fields.

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Insulin Glargine "All to Target" Trial

Computer-based Screening for Diabetic Retinopathy

Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Onco-primary Care Networking to Support TEAM-based Care

Naturlose (D-Tagatose) Efficacy Evaluation Trial

The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin